XNAS
ATPC
Market cap205mUSD
Jun 18, Last price
3.88USD
1D
42.12%
1Q
77.17%
IPO
-99.94%
Name
Agape ATP Corp
Chart & Performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Agape ATP Corporation, an investment holding enterprise, operates out of Malaysia, providing a variety of health and wellness products in addition to health solution advisory services. The company structures its extensive offerings into four main program categories: ATP Zeta Health Program, ÉNERGÉTIQUE, BEAUNIQUE, and E.A.T.S., each encompassing a unique selection of goods and services. Its product range includes the ATP series, featuring ATP1s Survivor Select for essential bodily nutrients, ATP3 Ionized Cal-Mag as a vital calcium and magnesium supplement, ATP4 Omega Blend supplying crucial omega 3 and 6 fatty acids, and ATP5 BetaMaxx for immune system enhancement. Other products in this line address specific needs, such as AGN-Vege Fruit Fiber for digestive tract health, AGP1-Iron to combat iron deficiency, and YFA-Young Formula for anti-aging and youthful appearance maintenance. Under the BEAUNIQUE brand, consumers can find Mito+, an antioxidant beverage formulated for cellular, immune, metabolic, brain, and skin health, alongside Trim+, which works to inhibit carbohydrate digestion and reduce sugar absorption. The ÉNERGÉTIQUE brand specializes in skincare, offering various energy masks (Med-Hydration, Med-Whitening, Med-Firming), a hyaluronic acid serum, and a mousse facial cleanser. Additionally, the company markets soy protein isolate powder and an antioxidant under the Livo5 label. Beyond its product sales, Agape ATP Corporation actively advocates for a healthy lifestyle through online articles, structured programs, events, and public campaigns, while also delivering therapeutic health services. The company was founded in 2016 and maintains its corporate headquarters in Kuala Lumpur, Malaysia.
IPO date
Sep 17, 2018
Employees
30
Domiciled in
MY
Incorporated in
US
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2019‑06 | 2018‑06 | 2017‑06 | 2016‑06 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||